Neuroscience Development:
Are We Measuring What Matters?
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Neuroscience clinical development is evolving across Alzheimer’s disease, Parkinson’s disease, psychiatry and other complex CNS disorders. Disease heterogeneity, trial accessibility, endpoint selection and variability in treatment response are challenging traditional approaches to how sponsors identify patients, measure treatment effects and make development decisions.
This webinar will explore how sponsors are addressing these challenges across neuroscience. Panelists will examine approaches to patient identification and enrollment, why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.
Examples from neurodegenerative disease, psychiatry and emerging fields such as psychedelic medicine will illustrate how patient populations, endpoints and measures of treatment response are influencing trial design and execution. The discussion will also look ahead at the scientific, operational and regulatory trends likely to shape neuroscience development over the next five years.
Attendees will gain practical insights into how sponsors are adapting development strategies across CNS disorders, from identifying appropriate patient populations and selecting meaningful endpoints to navigating evolving trial requirements and applying study data to development decisions.
Register for this webinar to learn how evolving approaches to neuroscience clinical development can inform patient identification, endpoint selection and future clinical trial strategies.
Who should attend
- Clinical Development, Clinical Operations and Program Leadership teams managing neuroscience studies
- Medical Affairs, Clinical Science and Trial Strategy leaders responsible for CNS development programs
- Translational Medicine and Neuroscience Research teams advancing therapies in Alzheimer’s disease, Parkinson’s disease, psychiatry and emerging areas such as psychedelic medicine
- Biotech and pharmaceutical sponsors seeking insight into evolving approaches to patient identification, outcome measurement and neuroscience trial design
What you will learn
- How sponsors are addressing patient identification challenges in Alzheimer’s disease, Parkinson’s disease and psychiatric disorders, as disease heterogeneity continues to complicate enrollment and study execution
- What emerging therapeutic areas such as psychedelic medicine are teaching the industry about endpoint selection, treatment response and the future of neuroscience trial design
- Why traditional approaches to measuring outcomes are being re-examined and how sponsors are evaluating new ways to demonstrate clinically meaningful treatment effects across CNS disorders
- The scientific, operational and regulatory trends most likely to shape neuroscience development over the next five years, from neurodegenerative disease to psychiatry
Featured Speakers
(Moderator) Jason Tibbs
Jason Tibbs serves as Global Therapeutic Head, Neuroscience & Ophthalmology at Syneos Health. With 20 years of clinical research experience, including 15 years in drug development and 5 years in academic research, he brings extensive expertise in global clinical operations and program leadership. Prior to his current role, he lived and worked across South Africa, Canada and the United States, building broad international experience within the drug development industry. He has provided operational leadership and oversight for numerous global neuroscience, cardiovascular, respiratory and oncology studies, driving consistency, quality and delivery excellence across complex clinical development programs.
Alexandria Wise
Alexandria Wise serves as Head of Research & Development and Scientific Strategy, Neuroscience at Syneos Health. As a licensed Clinical Psychologist specializing in neuropsychology, she brings 28 years of experience across clinical research, psychiatry drug development and scientific strategy. Prior to her current role, she held leadership positions within large academic medical centers and CROs helping advance investigational medicines for psychiatric and neurological disorders. An active leader in digitally optimized trials and treatments, she has directed numerous global clinical programs and partnered with sponsors to develop innovative and effective clinical development strategies across the neuroscience landscape.
Zia Choudhry
Zia Choudhry serves as Head of Research & Development and Scientific Strategy at Syneos Health. As a Physician-Scientist with expertise spanning neuroscience, precision medicine, rare diseases and oncology, he brings more than 20 years of experience across clinical care, drug development, medical affairs and research leadership. Prior to joining Syneos Health, he held senior leadership roles across the biopharmaceutical industry, leading therapeutic strategy, clinical development and cross-functional medical teams. He is recognized for advancing innovative approaches in biomarker research, personalized medicine and digital health, helping sponsors develop and deliver patient-centered solutions across complex therapeutic areas.
Partner for this event
Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. They translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Together they share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. They support a diverse, equitable and inclusive culture.
To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.